Your browser doesn't support javascript.
loading
Machine Learning Enables Accurate Prediction of Asparagine Deamidation Probability and Rate.
Delmar, Jared A; Wang, Jihong; Choi, Seo Woo; Martins, Jason A; Mikhail, John P.
Afiliação
  • Delmar JA; Analytical Sciences, Biopharmaceutical Development, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA.
  • Wang J; Analytical Sciences, Biopharmaceutical Development, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA.
  • Choi SW; David H. Koch School of Chemical Engineering Practice, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Martins JA; David H. Koch School of Chemical Engineering Practice, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Mikhail JP; David H. Koch School of Chemical Engineering Practice, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Mol Ther Methods Clin Dev ; 15: 264-274, 2019 Dec 13.
Article em En | MEDLINE | ID: mdl-31890727
ABSTRACT
The spontaneous conversion of asparagine residues to aspartic acid or iso-aspartic acid, via deamidation, is a major pathway of protein degradation and is often seriously disruptive to biological systems. Deamidation has been shown to negatively affect both in vitro stability and in vivo biological function of diverse classes of proteins. During protein therapeutics development, deamidation liabilities that are overlooked necessitate expensive and time-consuming remediation strategies, sometimes leading to termination of the project. In this paper, we apply machine learning to a large (n = 776) liquid chromatography-tandem mass spectrometry (LC-MS/MS) dataset of monoclonal antibody peptides to create computational models for the post-translational modification asparagine deamidation, using the random decision forest method. We show that our categorical model predicts antibody deamidation with nearly 5% increased accuracy and 0.2 MCC over the best currently available models. Surprisingly, our model also paces or outperforms advanced and conventional models on an independent non-antibody dataset. In addition to deamidation probability, we are able to accurately predict deamidation rate (R2 = 0.963 and Q2 = 0.822), a capability with no peer in current models. This method should enable significant improvement in protein candidate selection, especially in biopharmaceutical development, and can be applied with similar accuracy to enzymes, monoclonal antibodies, next-generation formats, vaccine component antigens, and gene therapy vectors such as adeno-associated virus.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article